Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1799-7
Abstract: PurposeAberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study… read more here.
Keywords: met alterations; cell lung; metex14 mutations; non small ... See more keywords
Real-world insights into patients with advanced NSCLC and MET alterations.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.06.015
Abstract: OBJECTIVES To describe characteristics, treatment and outcomes of non-small cell lung cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET amplification [METamp]) in real-world clinical care. METHODS This non-interventional cohort study… read more here.
Keywords: metamp; real world; line; met alterations ... See more keywords
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032368
Abstract: Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited… read more here.
Keywords: oncology; met alterations; real life; nsclc harboring ... See more keywords